{"id":"travoprost-timolol-therapy","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Conjunctival hyperemia"},{"rate":"10-20","effect":"Eye irritation/discomfort"},{"rate":"5-15","effect":"Iris pigmentation increase"},{"rate":"5-10","effect":"Eyelash growth"},{"rate":"null","effect":"Bradycardia"},{"rate":"null","effect":"Bronchospasm"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Travoprost is a prostaglandin F analog that binds to prostaglandin F receptors and enhances drainage of aqueous humor through the uveoscleral pathway. Timolol is a non-selective beta-adrenergic antagonist that decreases aqueous humor production by inhibiting beta-2 adrenergic receptors on the ciliary body. Together, these complementary mechanisms provide additive intraocular pressure reduction.","oneSentence":"Travoprost/timolol is a fixed-dose combination that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (travoprost) and decreasing aqueous humor production (timolol).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:02.894Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT00757835","phase":"PHASE4","title":"24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2008-05","conditions":"Glaucoma","enrollment":40},{"nctId":"NCT00981786","phase":"PHASE4","title":"24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-08","conditions":"Glaucoma","enrollment":51},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02312544","phase":"PHASE2","title":"Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2014-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":72},{"nctId":"NCT01845038","phase":"PHASE1","title":"Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2013-04","conditions":"Glaucoma","enrollment":41},{"nctId":"NCT01230736","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Glaucoma","enrollment":105},{"nctId":"NCT00519753","phase":"PHASE4","title":"Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-08","conditions":"Glaucoma","enrollment":522},{"nctId":"NCT00333125","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":319},{"nctId":"NCT00382226","phase":"PHASE4","title":"IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-09","conditions":"Glaucoma","enrollment":195},{"nctId":"NCT02003391","phase":"PHASE4","title":"Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":157},{"nctId":"NCT02097719","phase":"PHASE4","title":"Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":100},{"nctId":"NCT01881126","phase":"PHASE4","title":"An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":93},{"nctId":"NCT01652664","phase":"PHASE3","title":"Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":"Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients","enrollment":184},{"nctId":"NCT00887029","phase":"PHASE4","title":"A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Ophthalmic Consultants Centres, Canada","startDate":"2009-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":54},{"nctId":"NCT01514721","phase":"PHASE4","title":"Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-06","conditions":"Glaucoma","enrollment":37},{"nctId":"NCT00465803","phase":"PHASE3","title":"A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":81},{"nctId":"NCT00760539","phase":"PHASE3","title":"Safety and Efficacy of Travoprost/Timolol BAC-free","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-06","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":87},{"nctId":"NCT00672997","phase":"PHASE3","title":"A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":301},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT00444184","phase":"PHASE4","title":"24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2007-03","conditions":"Glaucoma","enrollment":32},{"nctId":"NCT00331240","phase":"PHASE3","title":"24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-03","conditions":"Primary Open Angle Glaucoma, Exfoliation Syndrome","enrollment":32},{"nctId":"NCT01779284","phase":"PHASE4","title":"Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2012-01","conditions":"Glaucoma","enrollment":42},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60},{"nctId":"NCT01696383","phase":"PHASE4","title":"Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2013-02","conditions":"Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01510132","phase":"PHASE4","title":"Travacom Post Marketing Surveillance Study","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2012-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT00508469","phase":"PHASE4","title":"Adherence Assessment With Travalert Dosing Aid","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":102},{"nctId":"NCT00471068","phase":"PHASE4","title":"Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":46},{"nctId":"NCT00311389","phase":"PHASE3","title":"A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-01","conditions":"Glaucoma, Open-angle, Ocular Hypertension","enrollment":408},{"nctId":"NCT00293800","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT00293787","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":156},{"nctId":"NCT00471380","phase":"PHASE4","title":"A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":46},{"nctId":"NCT00763061","phase":"PHASE4","title":"Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-05","conditions":"Glaucoma","enrollment":111},{"nctId":"NCT00348023","phase":"PHASE4","title":"Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Glaucoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DuoTrav BAK Free"],"phase":"marketed","status":"active","brandName":"Travoprost/timolol therapy","genericName":"Travoprost/timolol therapy","companyName":"Aristotle University Of Thessaloniki","companyId":"aristotle-university-of-thessaloniki","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Travoprost/timolol is a fixed-dose combination that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (travoprost) and decreasing aqueous humor production (timolol). Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}